News ZYUS Life Sciences Corporation

Equities

ZYUS

CA9899601095

Market Closed - Toronto S.E. Other stock markets 03:43:29 2024-04-23 pm EDT			5-day change	1st Jan Change
1.03 ^CAD	+3.00%		+6.19%	+14.44%

Apr. 23	ZYUS Life Sciences Receives US Patent for Pain Management Drug Candidate	MT
Mar. 05	Calian Group and MDA Brief: Calian Says "Strengthens Nuclear Capability" with Acquisition of MDA Ltd. Nuclear Assets	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ZYUS Life Sciences Receives US Patent for Pain Management Drug Candidate	Apr. 23	MT
ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management	Apr. 23	BU
Calian Group and MDA Brief: Calian Says "Strengthens Nuclear Capability" with Acquisition of MDA Ltd. Nuclear Assets	Mar. 05	MT
Calian Group Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	Feb. 20	MT
Calian Group Brief: Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	Feb. 20	MT
ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke	Feb. 02	AQ
ZYUS Life Sciences Appoints Dr. Hance Clarke to Clinical Advisory Committee	Feb. 01	MT
Zyus Appoints Dr. Hance Clarke as Clinical Advisory Committee	Feb. 01	CI
ZYUS Strengthens Leadership Team with Appointment of Vice President of Clinical Research	Jan. 10	AQ
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Management	Dec. 06	AQ
ZYUS Life Sciences Corp. Announces Phase 2 Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Care	Dec. 05	MT
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin®? Softgel Capsules for Advanced Cancer Pain Management	Dec. 05	CI
ZYUS Life Sciences Corporation Reports Q3 2023 Results	Nov. 30	AQ
ZYUS Life Sciences Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin Softgels	Nov. 22	AQ
ZYUS Life Sciences Corp. Brief: Announced "Positive" Phase I Clinical Trial Results for Trichomylin Softgels	Nov. 21	MT
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels	Nov. 21	CI
ZYUS Life Sciences Corporation Announces New Director of Investor Relations and Capital Markets	23-10-25	AQ
ZYUS Life Sciences Corporation Appoints Tim Miller as Director of Investor Relations and Capital Markets, Effective November 1, 2023	23-10-24	CI
ZYUS Life Sciences Corporation Obtains Health Canada Security Clearance for New Board Member Wayne Brownlee	23-09-01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ZYUS Life Sciences Corporation

Equities

ZYUS

CA9899601095

Summary

Filters